In addition to a demand of a larger clinical cohort, to achieve better outcomes by using 3-BP or other HK2 inhibitors, as stated in Supplementary Table 4, to cure cancer in clinic, a very recent article suggested that simultaneous or sequential treatment of 3-BP and other conventional therapeutic agents needs to be tested for optimal tumor-killing ability, and/or localized delivery of 3-BP directly into tumor tissues should be considered without affecting normal cells (85). This evidence concerns the gene HK2 and cancer.